Special Issue

Photodynamic Therapy (4th Edition)

Message from the Guest Editor

In medicine, the use of photodynamic therapy (PDT) is now well documented and codified for the treatment of oncological and non-oncological diseases, including macular degeneration of the retina and carcinomas of the esophagus and lung. In dermatology, the applications of PDT include treating oncological diseases such as basal cell carcinoma, squamous cell carcinoma, and actinic keratoses. It is also used to treat non-oncological issues, such as bacterial, fungal, viral, immunological, or inflammatory infections in chronic wounds. Moreover, in cosmetology, it is used for photorejuvenation. Three important mechanisms are responsible for the efficacy of PDT: (1) direct tumor cell death or inflammation, (2) damage to tumor vessels, and (3) an immunological response associated with leukocyte stimulation and the release of interleukins and other cytokines, growth factors, complement components, acute phase proteins, and other immunoregulators. This Special Issue will continue to cover all aspects of photodynamic therapy, including new natural and synthetic photosensitizers, biomaterials, nanotechnologies, in vitro and in vivo studies.

Guest Editor

Dr. Stefano Bacci

Research Unit of Histology and Embryology, Department of Biology, University of Florence, Florence, Italy

Deadline for manuscript submissions

31 October 2025

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/235523

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).